Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy

Fig. 3

Bioeffects of PIAS3 in breast cancer cells. a Ectopic PIAS3 overexpression increased the expression levels of cyclin D1 in estrogen receptor (ER)-positive MCF-7 and T47D cells, but decreased those of cyclin D1 in ER-negative MDA-MB-231 and SKBR3 cells. b The XTT results revealed that ectopic PIAS3 overexpression increased proliferation of ER-positive MCF-7 and T47D cells but inhibited proliferation of ER-negative MDA-MB-231 and SKBR3 cells. Ectopic PIAS3 overexpression attenuated the cytotoxicity of Tam to ER-positive MCF-7 cells. c Increased cyclin D1 expression upon ectopic PIAS3 overexpression was not reversed by Tam, but was inhibited by 17β-estradiol (E2) in ER-positive MCF-7 cells. d Chromatin immunoprecipitation revealed that ectopic PIAS3 overexpression decreased its binding to the conserved STAT3-binding element of the cyclin D1 promoter. Tam did not reverse the decreased trend of PIAS3 binding to the cyclin D1 promoter, while E2 increased PIAS3 binding to the cyclin D1 promoter after ectopic PIAS3 overexpression in ER-positive MCF-7 cells

Back to article page